To determine whether CD137 is a potential therapeutic target for enhancing NK cell function against gastric cancer, we investigated whether rhCD137L could enhance trastuzumab-mediated NK cell cytotoxicity (Fig 2). Here, TNFRSF9 is linked to gastric cancer.